DXCM241206P68000
- 0.04
- 0.000.00%
DexCom Newsroom
Wells Fargo Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $90
BofA Securities Maintains DexCom(DXCM.US) With Buy Rating
Wells Fargo Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $90
Wells Fargo Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $90
Wells Fargo Sticks to Its Buy Rating for Dexcom (DXCM)
Wells Fargo Remains a Buy on Dexcom (DXCM)
J.P. Morgan Downgrades DexCom(DXCM.US) to Hold Rating, Cuts Target Price to $85
A Quick Look at Today's Ratings for DexCom(DXCM.US), With a Forecast Between $85 to $115
J.P. Morgan Sticks to Its Hold Rating for Dexcom (DXCM)
DexCom Is Maintained at Neutral by JP Morgan
Dexcom's Strategic Resilience and Growth Prospects Support Buy Rating
Leerink Partners Maintains Outperform on DexCom, Lowers Price Target to $87
DexCom Price Target Raised to $90.00/Share From $80.00 by Wells Fargo
A Quick Look at Today's Ratings for DexCom(DXCM.US), With a Forecast Between $75 to $120
DexCom Analyst Ratings
Dexcom (DXCM) Gets a Buy From Stifel Nicolaus
Nephron Adjusts Price Target on DexCom to $110 From $105
Wells Fargo Keeps Their Buy Rating on Dexcom (DXCM)
Analysts Offer Insights on Healthcare Companies: Dexcom (DXCM) and Inozyme Pharma (INZY)
Optimistic Outlook and Strategic Advancements Justify Buy Rating for Dexcom